Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
103K characters. Original on sec.gov ·
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Business Development Transactions
Below is a summary of significant business development activity thus far in 2026.
In September 2026, Merck and SciBrunch Therapeutics Co., Ltd. (SciBrunch) closed an exclusive license agreement for MK-2690 (SPR2015), a potent and selective novel, investigational, preclinical, molecular glue KRAS G12D (ON) inhibitor, targeting cancers and tumors characterized by the KRAS G12D mutation. Under the agreement, SciBrunch granted Merck exclusive rights to develop, manufacture and commercialize MK-2690 (SPR2015) worldwide. The Company recorded a charge to Research and development expenses of $400 million in the third quarter and first nine months of 2026, or $0.12 per share, for the upfront payment, which is expected to be paid in the fourth quarter of 2026. SciBrunch is also eligible to receive future contingent development-related, regulatory, and, if approved, sales-based milestone payments.
In July 2026, Merck acquired TARGAN, a privately held company developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for $647 million. The acquisition will broaden Merck Animal Health’s portfolio in commercial poultry operations with WingScan, an automated solution that uses vision technology for gender identification. This acquisition also brings the capability for a high-speed precision ocular spray technology, which administers respiratory and coccidiosis vaccines, among others, to day-old chicks. In addition, TARGAN has the potential to develop additional biodevices within poultry and other livestock species. Merck recorded a realized gain of $68 million to Other (income) expense, net in the first nine months of 2026 related to an existing investment that Merck held in TARGAN. The transaction was accounted for as a business combination. There are no future contingent payments associated with the acquisition.
In May 2026, Merck acquired Terns Pharmaceuticals, Inc. (Terns), a clinical-stage oncology company, for $6.8 billion (including $606 million of payments to settle share-based equity awards of which $433 million related to unvested equity awards). Through this acquisition, Merck acquired Terns’ lead candidate, MK-4208 (formerly TERN-701), a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI) currently being evaluated in a Phase 1/2 trial for patients with Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia previously treated with at least one prior TKI and who experienced treatment failure, suboptimal response or treatment intolerance. The transaction was accounted for as an asset acquisition because MK-4208 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded a charge of $5.7 billion to Research and development expenses (which primarily represented acquired in-process research and development [IPR&D] with no alternative future use), or $2.31 per share, in the first nine months of 2026, as well as net assets of $1.1 billion, including cash of $505 million, investments of $487 million, deferred tax assets of $190 million, and other net liabilities of $105 million. There are no future contingent payments associated with the acquisition.
In January 2026, Merck acquired Cidara Therapeutics, Inc. (Cidara), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $9.2 billion (including $570 million of payments to settle share-based equity awards of which $406 million related to unvested equity awards). Cidara’s lead DFC candidate, MK-1406 (formerly CD388), is a long-acting antiviral designed to prevent seasonal and pandemic influenza. MK-1406 is currently being evaluated in a Phase 3 trial among adult and adolescent participants who are at higher risk of developing complications from influenza. The transaction was accounted for as an asset acquisition because MK-1406 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded a charge of $9.0 billion to Research and development expenses (which primarily represented acquired IPR&D with no alternative future use), or $3.62 per share, in the first nine months of 2026, as well as net assets of $332 million. Under a previous license agreement between Cidara and J&J Innovative Medicine (a Johnson & Johnson company, previously Janssen Pharmaceuticals, Inc.), which was assumed by Merck, J&J Innovative Medicine is eligible to receive regulatory and sales-based milestones related to MK-1406.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure.
In 2021, the U.S. Congress passed the American Rescue Plan Act, which included a provision that eliminated the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024.
In 2022, the U.S. Congress passed the Inflation Reduction Act (IRA), which made significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits (which went into effect in 2025), and government price-setting for certain Medicare Part D drugs (which went into effect in 2026) and Medicare Part B drugs (starting in 2028). The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), selected Januvia (sitagliptin) in 2023 for the first year of the IRA’s “Drug Price Negotiation Program” (Program), and selected Janumet (sitagliptin and metformin HCl) and Janumet XR (sitagliptin and metformin HCl extended release) in 2025 for the second year of the IRA’s Program. Pursuant to the IRA’s Program, the government set a price for Januvia, which became effective on January 1, 2026, and set a price for Janumet and Janumet XR, which will become effective on January 1, 2027. In addition, in January 2026, HHS announced that Lenvima (lenvatinib) has been selected for government price setting, the set price for which will become effective on January 1, 2028. Furthermore, the Company expects that Keytruda (pembrolizumab) will be selected in 2027 for government price setting, which
- 32 -
would become effective on January 1, 2029; a pending CMS proposed rule may subject Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) to price setting at the same time. Government price setting may also impact pricing in the private market negatively affecting the Company’s performance.
Additionally, increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company’s ability to identify inappropriate discounts are having a negative impact on Company performance. Furthermore, the Executive Branch and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs.
In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first nine months of 2026 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In July 2026, the German parliament approved the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG), a comprehensive health care reform law designed to reduce health insurance expenditures. The legislation introduces significant cost-containment measures that directly impact the pharmaceutical industry, including the Company, with the majority of the provisions taking effect on January 1, 2027. The Company is currently evaluating the implications of the GKV-BStabG on its business; however, the provisions of this law will exert significant downward pressure on revenues in Germany, particularly with respect to Keytruda.
The Company anticipates all of these actions and additional actions in the future will continue to negatively affect sales and profits.
In May 2025, the U.S. presidential administration issued an Executive Order (EO) intended to encourage or impose the use of “most-favored-nation” pricing to tie U.S. prescription drug prices to prices in selected comparably developed nations. In July 2025, the Company and other pharmaceutical companies received letters from the U.S. presidential administration with a request to agree to the administration’s “most-favored-nation” drug pricing goals by September 29, 2025. Further to the letter received from the administration, in December 2025, the Company announced that it had entered into a three-year agreement (MFN Agreement) with the U.S government that addressed the four policy goals of the administration’s July letter. The Company is providing Januvia, Janumet and Janumet XR through a direct-to-patient program at affordable prices for eligible patients in the U.S., and will be expanding the program in the future to include Lipfendra (enlicitide). The Company also agreed to offer its existing medicines at discounted prices to Medicaid (excluding certain products) and in June 2026 signed an agreement with CMS to participate in the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model, a voluntary model through which participating state Medicaid agencies receive pricing for certain medications aligned to prices paid in select countries. As a result of the Company’s participation in the GENEROUS Model, it expects to be exempt from the Global Benchmark for Efficient Drug Pricing (GLOBE) Model through December 2030. GLOBE is a mandatory Medicare Part B model that will apply an international benchmark to certain physician-administered medicines based on reference pricing from certain countries. Additionally, the Company agreed that products launched during the term of the MFN Agreement (with certain exceptions) will be subject to “most-favored-nation” pricing in reference to prices for such products in a specified group of countries (MFN Countries). Finally, the Company agreed to repatriate and share with the Federal government a portion of foreign revenue received by the Company as a result of the government’s successful trade policy efforts. Additionally, the Company reached an agreement with the U.S. Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to make investments in the U.S. to reshore manufacturing for American patients.
Operating Results
Sales
| Three Months Ended September 30, | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||||
| ($ in millions) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||||||||||||||||
| U.S. | $ | 10,615 | $ | 10,012 | 6 | % | 6 | % | $ | 29,146 | $ | 27,371 | 6 | % | 6 | % | |||||||||||||||||||||||||||||||
| International | 7,471 | 7,264 | 3 | % | 2 | % | 21,832 | 21,240 | 3 | % | — | % | |||||||||||||||||||||||||||||||||||
| Total | $ | 18,085 | $ | 17,276 | 5 | % | 4 | % | $ | 50,978 | $ | 48,611 | 5 | % | 4 | % |
U.S. plus international may not equal total due to rounding.
Worldwide sales were $18.1 billion and $51.0 billion in the third quarter and first nine months of 2026, respectively, representing increases of 5% compared with the same periods of 2025, primarily driven by growth in the oncology and cardiometabolic, respiratory and specialty franchises, as well as animal health, partially offset by a decline in the vaccines and infectious diseases franchise. U.S. sales in both the third quarter and first nine months of 2026 benefited from the timing of purchases by approximately $550 million.
-
Growth in the oncology franchise was largely due to the performance of Keytruda/Keytruda Qlex and Welireg (belzutifan), offset in part by lower alliance revenue related to Koselugo (selumetinib) resulting from an amendment to the collaboration agreement with AstraZeneca PLC (AstraZeneca).
-
Growth in the cardiometabolic, respiratory and specialty franchise was largely attributable to the continued uptake of Winrevair (sotatercept-csrk), as well as the inclusion of sales of Ohtuvayre (ensifentrine), which was obtained as part of the October 2025 acquisition of Verona Pharma plc (Verona Pharma), partially offset by lower sales of Januvia and Janumet.
-
Animal health sales growth was due to the performance of both livestock and companion animal products.
- 33 -
- Lower revenue in the vaccines and infectious diseases franchise was primarily due to lower sales of Lagevrio (molnupiravir), Bridion (sugammadex), Dificid (fidaxomicin), and Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine), partially offset by growth in Prevymis (letermovir), Enflonsia (clesrovimab-cfor), Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) and Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine Recombinant) / Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). The overall U.S. vaccines market has experienced a contraction negatively affecting sales.
See Note 15 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows. All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or service marks are those of their respective owners.
Pharmaceutical Segment
Oncology
| Three Months Ended September 30, | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||||
| ($ in millions) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||||||||||||||||
| Keytruda/Keytruda Qlex | $ | 8,601 | $ | 8,147 | 6 | % | 6 | % | $ | 25,001 | $ | 23,308 | 7 | % | 6 | % | |||||||||||||||||||||||||||||||
| Alliance Revenue - Lynparza (1) | 352 | 379 | (7) | % | (7) | % | 1,059 | 1,061 | — | % | (2) | % | |||||||||||||||||||||||||||||||||||
| Welireg | 307 | 196 | 56 | % | 58 | % | 776 | 496 | 57 | % | 57 | % | |||||||||||||||||||||||||||||||||||
| Alliance Revenue - Reblozyl (2) | 177 | 136 | 31 | % | 31 | % | 448 | 361 | 24 | % | 24 | % | |||||||||||||||||||||||||||||||||||
| Alliance Revenue - Koselugo (3) | 13 | 214 | (94) | % | (94) | % | 183 | 301 | (39) | % | (39) | % |
(1) Alliance revenue for Lynparza represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
(2) Alliance revenue for Reblozyl represents royalties (see Note 3 to the condensed consolidated financial statements).
(3) Alliance revenue for Koselugo includes $150 million in the first nine months of 2026 and $200 million in the third quarter and first nine months of 2025 related to an amendment to the collaboration agreement with AstraZeneca in August 2025, which revised the payment structure. (See Note 3 to the condensed consolidated financial statements for more information on this collaboration, including the above referenced amendment.)
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved in over 45 indications in the U.S., including 19 tumor types and 2 tumor-agnostic indications, and has similarly been approved in markets worldwide for many of these indications. Keytruda Qlex is a subcutaneously-administered fixed combination of pembrolizumab and berahyaluronidase alfa, which enhances dispersion and permeability to enable subcutaneous administration of pembrolizumab. Keytruda Qlex, which was initially approved by the FDA in September 2025, is approved in the U.S. in solid tumor indications approved for Keytruda. In November 2025, the European Commission (EC) approved a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) of Keytruda (to be marketed as Keytruda SC) for use across Keytruda indications for adults in Europe. Timing for commercial availability of Keytruda SC in individual European Union (EU) countries for approved indications will vary by country and depend on multiple factors, including the completion of reimbursement procedures and the outcome of litigation with Halozyme, Inc. As discussed in Note 8 to the condensed consolidated financial statements, preliminary injunctions have been awarded against the Company, prohibiting continued sales of Keytruda SC in Denmark and Italy and preventing product launches in Germany, The Netherlands, Belgium, Ireland, and France. In September 2026, Japan’s Ministry of Health, Labor and Welfare (MHLW) approved subcutaneous pembrolizumab and berahyaluronidase alfa injection under the trademark Keyject for all Keytruda approved indications in Japan. The Keytruda and Keytruda Qlex clinical development programs include studies across a broad range of cancer types. See “Research and Development Update” below.
Combined global sales of Keytruda/Keytruda Qlex grew 6% and 7% in the third quarter and first nine months of 2026, respectively. Sales growth in the U.S. in both periods reflects higher net pricing and increased demand. Demand in the U.S. was driven by higher utilization across earlier-stage indications, including in certain types of triple-negative breast cancer (TNBC), bladder cancer, head and neck squamous cell carcinoma, and cervical cancer, as well as higher demand across multiple metastatic indications, in particular for the treatment of certain types of urothelial cancer. The timing of wholesaler purchases unfavorably affected U.S. Keytruda sales in the third quarter of 2026, but was largely offset by an increase in inventory in the channel (which is expected to unwind in the fourth quarter of 2026). Sales growth in international markets reflects increased uptake in earlier-stage indications, predominately for cervical, TNBC, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC), as well as higher demand in urothelial and endometrial cancer metastatic indications. The launch and reimbursement of new indications for Keytruda in the EU continues to have a negative impact on pricing in those markets. In addition, a biosimilar of Keytruda launched in Argentina in 2025 and further launches in smaller international markets have occurred during 2026. The Company anticipates the impact of biosimilar erosion to Keytruda sales will be immaterial in 2026.
Keytruda has received the following regulatory approvals thus far in 2026.
| Date | Approval | ||||
| February 2026 | China’s National Medical Products Administration (NMPA) approval for the first-line treatment of certain patients with primary advanced or recurrent endometrial cancer, based on the KEYNOTE-868 (NRG-GY018) trial. |
- 34 -
| February 2026 | U.S. Food and Drug Administration (FDA) approval in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express programmed death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥ 1 as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens, based on the KEYNOTE-B96 trial. | ||||
| February 2026 | Japan’s MHLW approval as part of a neoadjuvant and adjuvant treatment regimen with radiotherapy with or without chemotherapy for certain patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC), based on the KEYNOTE-689 trial. | ||||
| March 2026 | EC approval in combination with paclitaxel, with or without bevacizumab, for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumors express PD-L1 (CPS ≥1) and who have received one or two prior systemic treatment regimens, based on the KEYNOTE-B96 trial. | ||||
| June 2026 | FDA approval in combination with Welireg for the adjuvant treatment of adult patients with RCC with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the LITESPARK-022 trial. | ||||
| June 2026 | EC approval in combination with Padcev (enfortumab vedotin), an antibody-drug conjugate (ADC), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy, based on the KEYNOTE-905 trial. | ||||
| June 2026 | FDA approval in combination with Trodelvy (sacituzumab govitecan-hziy), a trophoblast cell-surface antigen 2 (TROP2)-directed ADC, for the first-line treatment of adult patients with unresectable locally advanced or TNBC whose tumors express PD-L1 (CPS ≥10), based on the KEYNOTE-D19 trial. | ||||
| June 2026 | China's NMPA approval in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer whose tumors express PD-L1 (CPS ≥1) and who have received prior first- or second-line systemic therapy, based on the KEYNOTE-B96 trial. | ||||
| July 2026 | FDA approval in combination with Padcev for expanded use as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for adults with MIBC, including those eligible for cisplatin-containing chemotherapy, based on the KEYNOTE-B15 trial. | ||||
| September 2026 | China’s NMPA approval for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 (CPS ≥1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin and then as a single agent, based on the KEYNOTE-689 trial. | ||||
| September 2026 | Japan's MHLW approval for the treatment of platinum-resistant recurrent ovarian cancer, based on the KEYNOTE-B96 trial. | ||||
| October 2026 | EC approval in combination with Padcev as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable MIBC, based on the KEYNOTE-B15 trial. |
Keytruda Qlex (available in some markets as Keytruda SC) received the following regulatory approvals thus far in 2026.
| Date | Approval | ||||
| February 2026 | FDA approval in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens, based on the KEYNOTE-B96 trial. | ||||
| March 2026 | EC approval in combination with paclitaxel, with or without bevacizumab, for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumors express PD-L1 (CPS ≥1) and who have received one or two prior systemic treatment regimens, based on the KEYNOTE-B96 trial. | ||||
| April 2026 | FDA approval of a label update based on results from the MK-3475A-F11 trial, which evaluated patient reported preference for subcutaneous administration of Keytruda Qlex over intravenous administration of Keytruda in participants with multiple tumor types. | ||||
| June 2026 | FDA approval in combination with Welireg for the adjuvant treatment of adult patients with RCC with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the LITESPARK-022 trial. | ||||
| June 2026 | EC approval in combination with Padcev, an ADC, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for adults with resectable MIBC who are ineligible for cisplatin-containing chemotherapy, based on the KEYNOTE-905 trial. | ||||
| June 2026 | FDA approval in combination with Trodelvy, a TROP2-directed ADC, for the first-line treatment of adult patients with unresectable locally advanced or TNBC whose tumors express PD-L1 (CPS ≥10), based on the KEYNOTE-D19 trial. | ||||
| July 2026 | FDA approval in combination with Padcev for expanded use as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for adults with MIBC, including those eligible for cisplatin-containing chemotherapy, based on the KEYNOTE-B15 trial. | ||||
| September 2026 | Japan’s MHLW approval for all indications approved in Japan for Keytruda, based on the MK-3475A-D77 trial. |
- 35 -
| September 2026 | China's NMPA approval for nineteen solid tumor indications, based on the MK-3475A-D77 trial. | ||||
| October 2026 | EC approval in combination with Padcev as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable MIBC, based on the KEYNOTE-B15 trial. |
The Company is a party to license agreements pursuant to which the Company pays royalties on net sales of Keytruda. Under the terms of the more significant of these agreements, Merck pays a royalty of 2.5% on worldwide net sales of Keytruda; this royalty (which also applies to net sales of Keytruda Qlex) will continue through 2026, terminating thereafter. The Company pays an additional 2% royalty on worldwide net sales of Keytruda (and on Keytruda Qlex following regulatory approval) to another third party; this royalty expired in the U.S. in 2024, expired in major European markets in the second half of 2025, but will continue to be paid on net sales of Keytruda and Keytruda Qlex in certain other international markets expiring at various dates through 2035. The royalty expenses are included in Cost of sales. The Company may be subject to additional royalties on net sales of Keytruda Qlex in the future under certain circumstances.
Lynparza (olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed and commercialized as part of a collaboration with AstraZeneca (see Note 3 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza declined 7% in the third quarter of 2026 primarily due to lower pricing in the U.S. and lower demand and pricing in China. Alliance revenue related to Lynparza in the first nine months of 2026 was consistent with the prior year period.
Welireg is approved for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors, certain adult patients with previously treated advanced RCC, and certain patients with pheochromocytoma and paraganglioma. Welireg is also approved in combination with Keytruda or Keytruda Qlex for the adjuvant treatment of certain adult patients with clear cell RCC following nephrectomy and in combination with Lenvima for the treatment of certain previously treated adult patients with advanced clear cell RCC. Sales of Welireg rose 56% and 57% in the third quarter and first nine months of 2026, respectively, primarily due to increased utilization in the U.S. for the advanced RCC monotherapy indication and as adjuvant treatment for RCC, as well as continued launch uptake in international markets, particularly in Japan.
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS) (see Note 3 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Alliance revenue related to this collaboration (consisting of royalties) increased 31% and 24% in the third quarter and first nine months of 2026, respectively, primarily due to strong underlying sales performance.
Koselugo is an oral, selective MEK inhibitor approved for the treatment of patients with neurofibromatosis type 1 who have symptomatic inoperable plexiform neurofibromas. Koselugo is part of a collaboration with AstraZeneca. Alliance revenue related to Koselugo declined 94% and 39% in the third quarter and first nine months of 2026, respectively, due to an amendment to the collaboration agreement with AstraZeneca in August 2025 that (subject to an annual election by AstraZeneca) discontinued the revenue and cost sharing provisions of the collaboration, and revised the payment structure. As a result of this amendment, alliance revenue related to Koselugo in the first nine months of 2026 reflects a $150 million payment received and for both the third quarter and first nine months of 2025 reflects a $150 million upfront payment received and the recognition of a $50 million regulatory approval milestone. See Note 3 to the condensed consolidated financial statements for additional information.
Vaccines and Infectious Diseases
| Three Months Ended September 30, | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||||
| ($ in millions) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||||||||||||||||
| Gardasil/Gardasil 9 | $ | 1,995 | $ | 1,749 | 14 | % | 14 | % | $ | 4,232 | $ | 4,202 | 1 | % | — | % | |||||||||||||||||||||||||||||||
| ProQuad | 296 | 273 | 8 | % | 8 | % | 730 | 668 | 9 | % | 8 | % | |||||||||||||||||||||||||||||||||||
| M-M-R II | 148 | 123 | 21 | % | 22 | % | 349 | 387 | (10) | % | (10) | % | |||||||||||||||||||||||||||||||||||
| Varivax | 286 | 288 | (1) | % | (1) | % | 781 | 777 | — | % | — | % | |||||||||||||||||||||||||||||||||||
| Capvaxive | 263 | 244 | 8 | % | 7 | % | 588 | 480 | 22 | % | 22 | % | |||||||||||||||||||||||||||||||||||
| Vaxneuvance | 195 | 226 | (14) | % | (13) | % | 545 | 685 | (20) | % | (22) | % | |||||||||||||||||||||||||||||||||||
| Bridion | 144 | 439 | (67) | % | (67) | % | 1,113 | 1,341 | (17) | % | (17) | % | |||||||||||||||||||||||||||||||||||
| Prevymis | 347 | 266 | 30 | % | 31 | % | 915 | 702 | 30 | % | 29 | % | |||||||||||||||||||||||||||||||||||
| Enflonsia | 187 | 79 | * | * | 190 | 79 | * | * | |||||||||||||||||||||||||||||||||||||||
| Dificid | 14 | 43 | (68) | % | (68) | % | 70 | 222 | (68) | % | (68) | % | |||||||||||||||||||||||||||||||||||
| Lagevrio | 17 | 138 | (88) | % | (88) | % | 49 | 323 | (85) | % | (85) | % |
** > 100%*
In January 2026, the acting director of the U.S. Centers for Disease Control and Prevention (CDC) announced changes to the child and adolescent immunization schedule (January announcement), reducing the number of routinely recommended vaccinations and creating three new categories: immunizations recommended for all children; immunizations
- 36 -
recommended for certain high-risk groups or populations; and immunizations based on shared clinical decision-making. Immunizations recommended for all children include vaccines for measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, Haemophilus influenzae type B (Hib), pneumococcal disease, human papillomavirus (HPV), and chickenpox (varicella). Immunizations recommended for certain high-risk groups or populations include respiratory syncytial virus (RSV), hepatitis A, hepatitis B, and dengue. Immunizations recommended based on shared clinical decision-making include rotavirus, hepatitis A, and hepatitis B. HHS has stated that immunizations for all of the diseases covered by the previous immunization schedule will still be available to anyone who wants them through Affordable Care Act insurance plans and federal insurance programs, including Medicaid, the Children’s Health Insurance Program, and the Vaccines For Children (VFC) program. Additionally, the trade association representing U.S. health insurers (AHIP) announced that its member health plans would continue to cover all immunizations that had been recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP) as of September 1, 2025, with no cost-sharing for patients through the end of 2027. On March 16, 2026, a federal district court in Massachusetts issued a preliminary injunction staying, among other things, the immunization schedule changes in the CDC’s January announcement. The government has appealed aspects of the district court ruling to the U.S. Court of Appeals for the First Circuit.
Combined worldwide sales of Gardasil and Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of HPV, grew 14% in the third quarter of 2026 primarily due to higher sales in the U.S. reflecting favorable public sector purchasing patterns and higher net pricing. Combined worldwide sales of Gardasil and Gardasil 9 grew 1% in the first nine months of 2026 primarily driven by higher sales in the U.S. reflecting higher net pricing and favorable public sector purchasing patterns, as well as higher demand in Europe and certain countries in the Asia Pacific region, largely offset by lower demand in China (discussed below) and in Japan, reflecting in part that the last date to initiate the first dose in Japan’s national immunization program catch-up cohort was in March 2025. The majority of the benefit to U.S. sales from favorable public sector purchasing patterns is expected to unwind in 2027. As previously disclosed, the Company suspended shipments to China in February 2025 given lower demand and elevated channel inventory levels in China. In April 2026, the Company entered into a revised supply contract with its distributor and commercialization partner in China, Chongqing Zhifei Biological Products Co., Ltd. In the second and third quarters of 2026, the Company made limited shipments to China; however, revenue associated with the revised supply contract is expected to be immaterial in 2026.
Among the changes in the CDC’s now-stayed January announcement referenced above was a reduction of the recommended doses for HPV vaccination of adolescents to a single dose. Gardasil 9 is currently indicated in the U.S. for a two-dose regimen in adolescents aged 9-14 and a three-dose regimen for those aged 15-45. Previous CDC recommendations for adolescents followed FDA-approved dosing. Many countries outside the U.S. have implemented a reduced dosing schedule for HPV vaccination in certain age groups. The Company anticipates that any negative effect of these recommendations or reduced dosing schedules on sales of Gardasil/Gardasil 9 will not be material.
The Company is a party to license agreements pursuant to which the Company pays royalties on net sales of Gardasil/Gardasil 9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on net sales of Gardasil/Gardasil 9 in the U.S. to one third party (this royalty expires in December 2028). The royalty expenses are included in Cost of sales.
Global sales of ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, grew 8% and 9% in the third quarter and first nine months of 2026, respectively, primarily due to higher demand in certain European markets, partially offset by lower sales in the U.S. The U.S. sales decline in both periods was driven by lower demand, offset in part by higher net pricing and, for the year-to-date period, the effects of CDC Pediatric Vaccine Stockpile activity in the prior year. As a result of manufacturing delays, in January 2025, the Company borrowed doses of ProQuad from the CDC Pediatric Vaccine Stockpile, which it partially replenished in the second quarter of 2025; the net effect of the borrowing and partial replenishment resulted in a net reduction to U.S. ProQuad sales of $49 million for the first nine months of 2025. Worldwide sales of M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, grew 21% in the third quarter of 2026 primarily due to favorable public sector purchasing patterns in the U.S. and higher demand in Latin America. Global sales of M-M-R II declined 10% in the first nine months of 2026 primarily due to lower demand and lower net pricing in the U.S., partially offset by higher demand in Latin America. Global sales of Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), were nearly flat in the first nine months of 2026 compared with the same prior year period as unfavorable CDC stockpile activity in the prior year as noted below, higher net pricing in the U.S., and higher demand in certain international markets, were offset by lower demand in the U.S. and Latin America.
In September 2025, the ACIP voted to recommend that children under the age of four years receive protection from chickenpox (varicella) as a standalone immunization rather than in combination with measles, mumps and rubella (MMR) vaccination, eliminating a previous shared clinical decision-making recommendation that allowed parents to choose combined MMR and varicella vaccine (MMRV) first-dose administration. The ACIP also voted to align the VFC program with this change. The acting CDC Director adopted the recommendation in October 2025. These ACIP recommendations are subject to the federal district court’s March 16, 2026 preliminary injunction, as described above. MMR and varicella vaccines remain recommended and funded through the VFC program for both the first and second doses. The Company is the only manufacturer in the U.S. of MMRV vaccine (ProQuad) and varicella vaccine (Varivax). The Company anticipates that any negative effect of these recommendations on sales of ProQuad will not be material.
In August 2026, the U.S. presidential administration issued an EO describing proposed federal policy for “Gold Standard Childhood Vaccine Recommendations.” Among other things, the EO included categories of childhood immunization
- 37 -
recommendations, recommended administration of the combined measles, mumps and rubella vaccine as three separate single-disease shots, recommended that all childhood immunizations be administered at separate medical visits to the maximum extent feasible, and advised U.S. states and territories to consider updating relevant laws and regulations concerning school immunization requirements. There currently are no approved U.S. monovalent measles, mumps or rubella single-antigen vaccines. Numerous medical, health and patient advocacy groups have voiced concerns with and/or opposition to the EO. The EO requires an HHS task force to present plans within 90 days of issuance to effectuate certain of its provisions, such as offering single-antigen alternatives to combination vaccines, reassessing vaccine timing and sequencing, developing alternatives to aluminum adjuvants, and improving safety monitoring and transparency.
Sales of Capvaxive, a vaccine for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by certain serotypes in individuals 18 years of age and older, and for the prevention of IPD caused by those serotypes in certain children and adolescents 2 to 17 years of age at increased risk, grew 8% and 22% in the third quarter and first nine months of 2026, respectively. Sales growth in both periods was largely due to launch uptake in several international markets, particularly in Europe and the Asia Pacific region, partially offset by the market dynamic of lower adult pneumococcal vaccination rates and lower net pricing in the U.S. which, for the year-to-date period, was partially offset by higher product demand. Capvaxive was approved in the U.S. in June 2024, in the EU in March 2025, and in Japan in August 2025 for use in adults. In June 2026, the FDA approved an expanded IPD indication for Capvaxive to include children and adolescents aged 2 through 17 years who have completed a primary pediatric pneumococcal vaccination series and have one or more chronic medical conditions that put them at an increased risk for pneumococcal disease. The EC approved a similar indication expansion in April 2026. The expanded approvals were based on data from the STRIDE-13 trial. Merck is a party to license agreements pursuant to which the Company pays royalties on net sales of Capvaxive. Under the terms of the most significant of these agreements, Merck pays a royalty of 7.25% on net sales of Capvaxive through 2026; this royalty will decline to 2.5% on net sales from 2027 through 2035. The royalty expenses are included in Cost of sales.
Worldwide sales of Vaxneuvance, a vaccine to help protect against IPD caused by certain serotypes, declined 14% in the third quarter of 2026 primarily due to lower sales in the U.S. reflecting unfavorable public sector purchasing patterns and lower demand. Worldwide sales of Vaxneuvance declined 20% in the first nine months of 2026 primarily due to approximately $70 million of favorable CDC stockpile activity in the U.S. in the prior year, of which approximately $60 million was offset by a drawdown of CDC stockpile inventory for Varivax (noted above) and RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), which resulted in a net neutral transaction. Lower demand in the U.S. and the Asia Pacific region due to competition also contributed to the sales decline in the first nine months of 2026. Merck is a party to license agreements pursuant to which the Company pays royalties on net sales of Vaxneuvance. Under the most significant of these agreements, Merck pays a royalty of 7.25% on net sales of Vaxneuvance through 2026; this royalty will decline to 2.5% on net sales from 2027 through 2035. The royalty expenses are included in Cost of sales.
Global sales of Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, declined 67% and 17% in the third quarter and first nine months of 2026, respectively, primarily due to generic competition in the U.S. following loss of market exclusivity in July 2026*.* The Company expects the U.S. Bridion sales decline to continue and anticipates the discontinuation of U.S. sales of Bridion in 2027 as generic market supply stabilizes.
Worldwide sales of Prevymis, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in certain high risk adult and pediatric recipients of an allogenic hematopoietic stem cell transplant and for prophylaxis of CMV disease in certain high risk adult and pediatric recipients of a kidney transplant, grew 30% in both the third quarter and first nine months of 2026 primarily due to higher demand globally, particularly in the U.S.
Sales of Enflonsia, a preventive, long-acting monoclonal antibody, for the prevention of RSV lower respiratory tract disease (LRTD) in neonates (newborns) and infants who are born during or entering their first RSV season, were $187 million and $190 million in the third quarter and first nine months of 2026, respectively, primarily driven by seasonal demand and associated inventory build in the U.S. and certain international markets. Enflonsia sales of $79 million in both the third quarter and first nine months of 2025 consisted of inventory stocking following U.S. launch. Enflonsia was approved in the U.S. in June 2025, in the EU in April 2026, and in Japan and China in June 2026, based on results from the CLEVER and SMART clinical trials. The timing for availability of Enflonsia in individual EU countries will vary by country and depend on multiple factors, including the completion of reimbursement procedures.
Worldwide sales of Dificid, a medicine for the treatment of C. difficile-associated diarrhea, declined 68% in both the third quarter and first nine months of 2026 due to generic competition in the U.S. Dificid lost market exclusivity in the U.S. in July 2025; accordingly, the Company is experiencing a significant decline in U.S. sales of Dificid and expects the decline to continue.
Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback Biotherapeutics LP (see Note 3 to the condensed consolidated financial statements). Sales of Lagevrio decreased 88% and 85% in the third quarter and first nine months of 2026, respectively, largely due to lower demand in Japan and the U.S. driven primarily by declining COVID-19 cases. The Company expects the Lagevrio sales decline to continue during 2026. In the U.S., where Lagevrio remains in Phase 3 development and is marketed under an Emergency Use Authorization (EUA), the Secretary of HHS provided advance notice on June 29, 2026 that the declaration supporting the EUAs pursuant to which Lagevrio and certain other COVID-19 drug and biologic products are marketed will terminate, effective June 29, 2027. Based on the Secretary’s June 2026 determination and advance notice of termination, the Company worked with the FDA to develop a plan for the disposition of Lagevrio in the U.S. by June 29, 2027. U.S. sales of Lagevrio were $25 million in the first nine months of 2026.
- 38 -
In April 2026, the FDA approved Idvynso, a once-daily, two-drug single-tablet regimen of doravirine, a non-nucleoside reverse transcriptase inhibitor, and islatravir, a next-generation nucleoside analog reverse transcriptase inhibitor, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine. Idvynso was also approved in Japan for these patients in March 2026. The approvals were based on the MK-8591A-051 and MK-8591A-052 clinical trials.
Cardiometabolic, Respiratory and Specialty
| Three Months Ended September 30, | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||||
| ($ in millions) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||||||||||||||||
| Winrevair | $ | 694 | $ | 360 | 93 | % | 94 | % | $ | 1,808 | $ | 976 | 85 | % | 85 | % | |||||||||||||||||||||||||||||||
| Januvia/Janumet | 380 | 624 | (39) | % | (39) | % | 1,383 | 2,043 | (32) | % | (32) | % | |||||||||||||||||||||||||||||||||||
| Ohtuvayre | 184 | — | — | — | 519 | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Alliance Revenue - Adempas/Verquvo (1) | 118 | 112 | 5 | % | 5 | % | 353 | 340 | 4 | % | 4 | % | |||||||||||||||||||||||||||||||||||
| Adempas | 78 | 82 | (5) | % | (3) | % | 234 | 229 | 2 | % | (1) | % |
(1) Alliance revenue for Adempas and Verquvo represents Merck’s share of profits from sales in Bayer AG’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Winrevair is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death. Sales of Winrevair rose 93% and 85% in the third quarter and first nine months of 2026, respectively, largely due to higher demand and a benefit from the timing of wholesaler and specialty pharmacy purchases in the U.S. (which is expected to unwind in the fourth quarter of 2026), as well as launch uptake in certain international markets, particularly in Europe and Japan. Winrevair was originally approved in the U.S. in March 2024, in the EU in August 2024, and in Japan in June 2025 (where it is being marketed as Airwin). Winrevair was approved for expanded indications in PAH based on the ZENITH trial in the U.S. in October 2025 and in the EU in January 2026. The U.S. product label was further updated to include the positive results of the HYPERION trial in September 2026. Winrevair is the subject of a license agreement pursuant to which Merck pays a 22% royalty on net sales of Winrevair to BMS. The royalty expenses are included in Cost of sales.
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 39% and 32% in the third quarter and first nine months of 2026, respectively, primarily driven by lower sales in the U.S. due to generic competition. Januvia and Janumet lost market exclusivity in the U.S. in May 2026 and Janumet XR lost market exclusivity in the U.S. in July 2026. Accordingly, the Company is experiencing significant declines in U.S. sales of these products and expects the declines to continue. The sales declines were also attributable to ongoing generic competition in most international markets and, for the year-to-date period, lower demand in China.
Ohtuvayre is an inhaled phosphodiesterases 3 and 4 (PDE3 and PDE4) inhibitor, which was approved in the U.S. in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. Ohtuvayre was obtained in conjunction with Merck’s October 2025 acquisition of Verona Pharma. Sales in the third quarter of 2026 reflect a modest unfavorable effect from the timing of specialty pharmacy purchases in the U.S. that favorably affected second quarter 2026 sales.
Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note 3 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of PAH and chronic pulmonary hypertension. Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Alliance revenue from the collaboration grew 5% and 4% in the third quarter and first nine months of 2026, respectively, primarily reflecting higher demand in Bayer’s marketing territories. The Company expects alliance revenue to decline for the full year of 2026 reflecting the loss of market exclusivity for Adempas in the U.S. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories were relatively consistent in the third quarter and first nine months of 2026 compared with the same prior year periods.
In July 2026, the FDA approved Lipfendra tablets as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lipfendra is a novel macrocyclic peptide and is the first FDA-approved oral PCSK9 inhibitor shown to lower LDL-C, also known as bad cholesterol. The approval was based on the CORALreef Lipids and CORALreef HeFH clinical trials.
- 39 -
Animal Health Segment
| Three Months Ended September 30, | % Change Excluding Foreign Exchange | Nine Months Ended September 30, | % Change Excluding Foreign Exchange | ||||||||||||||||||||||||||||||||||||||||||||
| ($ in millions) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||||||||||||||||
| Livestock | $ | 1,048 | $ | 1,023 | 2 | % | 2 | % | $ | 3,154 | $ | 2,909 | 8 | % | 5 | % | |||||||||||||||||||||||||||||||
| Companion Animal | 628 | 592 | 6 | % | 6 | % | 2,089 | 1,940 | 8 | % | 5 | % | |||||||||||||||||||||||||||||||||||
| $ | 1,676 | $ | 1,615 | 4 | % | 3 | % | $ | 5,243 | $ | 4,849 | 8 | % | 5 | % |
Sales of livestock products grew 2% in the third quarter of 2026 primarily due to higher demand for poultry products. Sales of livestock products grew 8% for the first nine months of 2026 primarily due to higher demand for ruminant and poultry products.
Sales of companion animal products grew 6% and 8% in the third quarter and first nine months of 2026, respectively, largely driven by new product launches, partially offset by lower pricing primarily for vaccines. Lower demand for other products in the portfolio also partially offset the sales decline in the year-to-date period. Sales of the Bravecto (fluralaner) line of products were $264 million in the third quarter of 2026, representing growth of 1%, or flat excluding the effect of foreign exchange, compared with the third quarter of 2025. Sales of the Bravecto line of products were $1.0 billion in the first nine months of 2026, representing growth of 8%, or 5% excluding the effect of foreign exchange, compared with the same period of 2025.
In July 2026, Merck acquired TARGAN, a privately held company developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry. See Note 2 to the condensed consolidated financial statements for more information.
In February 2026, the FDA approved Numelvi (atinvicitinib tablets), the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older.
Costs, Expenses and Other
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||||
| ($ in millions) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||||
| Cost of sales | $ | 4,892 | $ | 3,855 | 27 | % | $ | 13,482 | $ | 10,831 | 24 | % | |||||||||||||||||||||||
| Selling, general and administrative | 2,886 | 2,633 | 10 | % | 8,491 | 7,835 | 8 | % | |||||||||||||||||||||||||||
| Research and development | 4,537 | 4,234 | 7 | % | 26,871 | 11,903 | * | ||||||||||||||||||||||||||||
| Restructuring costs | 184 | 47 | * | 530 | 676 | (22) | % | ||||||||||||||||||||||||||||
| Other (income) expense, net | 27 | (238) | * | 262 | (281) | * | |||||||||||||||||||||||||||||
| $ | 12,526 | $ | 10,531 | 19 | % | $ | 49,636 | $ | 30,964 | 60 | % |
** > 100%*
Cost of Sales
Cost of sales increased 27% and 24% in the third quarter and first nine months of 2026, respectively. Cost of sales includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and license agreements, which totaled $1.1 billion and $621 million in the third quarter of 2026 and 2025, respectively, and $3.0 billion and $1.8 billion in the first nine months of 2026 and 2025, respectively. Additionally, cost of sales in the third quarter and first nine months of 2026 includes impacts of $83 million and $249 million, respectively, for the recognition of fair value step-up of inventories related to the October 2025 acquisition of Verona Pharma. Also included in cost of sales are expenses associated with restructuring activities, which amounted to $396 million and $110 million in the third quarter of 2026 and 2025, respectively, and $817 million and $311 million in the first nine months of 2026 and 2025, respectively, primarily reflecting accelerated depreciation and asset impairment charges related to manufacturing facilities to be fully or partially closed or divested, as well as contractual termination costs. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
Gross margin was 72.9% in the third quarter of 2026 compared with 77.7% in the third quarter of 2025. Gross margin was 73.6% in the first nine months of 2026 compared with 77.7% in the first nine months of 2025. The gross margin decline in both periods was primarily due to higher amortization of intangible assets, increased restructuring costs, the recognition of fair value step-up of inventories related to the October 2025 acquisition of Verona Pharma, and higher production costs. For the year-to-date period, the favorable effect of product mix partially offset the gross margin decline.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses increased 10% and 8% in the third quarter and first nine months of 2026, respectively, primarily due to higher administrative costs, as well as higher promotional costs in support of product launches. The unfavorable effect of foreign exchange also contributed to the increase in SG&A expenses in the year-to-date period.
- 40 -
Research and Development
Research and development (R&D) expenses were $4.5 billion in the third quarter of 2026, an increase of 7% compared with the third quarter of 2025, primarily driven by increased clinical development spending and higher charges for business development activity, partially offset by lower restructuring costs and a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone Life Sciences (Blackstone). R&D expenses increased to $26.9 billion in the first nine months of 2026 compared with $11.9 billion in the first nine months of 2025 primarily due to higher charges for business development activity, increased clinical development spending, and the unfavorable effect of foreign exchange, partially offset by a $600 million reduction in R&D expenses as part of a funding agreement with Blackstone, as well as lower restructuring costs.
Significant charges for business development activity in 2026 include the following (see Note 2 to the condensed consolidated financial statements for more information):
-
$400 million for a license agreement with SciBrunch (third quarter and first nine months of 2026)
-
$5.7 billion for the acquisition of Terns (first nine months of 2026)
-
$9.0 billion for the acquisition of Cidara (first nine months of 2026)
Significant charges for business development activity in 2025 include:
-
$300 million for completion of the technology transfer for MK-2010 (LM-299) from LaNova Medicines Ltd (LaNova) (third quarter and first nine months of 2025)
-
$200 million for a license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) (first nine months of 2025)
-
$100 million for the achievement of a developmental milestone related to the 2024 EyeBiotech Limited (EyeBio) acquisition (first nine months of 2025)
R&D expenses consist of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $2.9 billion and $8.2 billion in the third quarter and first nine months of 2026, respectively, (inclusive of a $200 million and $600 million benefit, respectively, from the Blackstone funding agreement discussed further in Note 2 to the condensed consolidated financial statements) and $2.7 billion and $8.0 billion for the third quarter and first nine months of 2025, respectively. Also included in R&D expenses are Animal Health research costs, upfront and milestone payments for collaboration and license agreements (including the charges related to SciBrunch, LaNova, Hengrui Pharma and EyeBio noted above), charges for transactions accounted for as asset acquisitions (including the charges for the acquisitions of Terns and Cidara noted above), and costs incurred by other divisions in support of R&D activities, including depreciation, production, and general and administrative, which in the aggregate were $1.6 billion and $1.3 billion for the third quarter of 2026 and 2025, respectively, and $18.6 billion and $3.6 billion for the first nine months of 2026 and 2025, respectively. R&D expenses also include restructuring costs of $233 million and $286 million for the third quarter of and first nine months of 2025, respectively, associated with contractual termination costs.
Restructuring Costs
In July 2025, the Company approved a restructuring program (2025 Restructuring Program) designed to position the Company for its next chapter of growth and to successfully advance its pipeline and launch new products across multiple therapeutic areas. As part of this program, the Company expects to eliminate certain positions in sales and administrative organizations, as well as research and development. The Company will, however, continue to hire employees into new roles across all strategic growth areas of the business. In addition, the Company will reduce its global real estate footprint and continue to optimize its manufacturing network, aligning the geography of its global manufacturing footprint to its customers and reflecting changes in the Company’s business. Most actions contemplated under the 2025 Restructuring Program are expected to be largely completed by the end of 2027, with the exception of certain manufacturing actions, which are expected to be substantially completed by the end of 2029. The cumulative pretax costs to be incurred by the Company to implement the program are estimated to be approximately $3.0 billion, of which approximately 60% will be cash, relating primarily to employee separation expense and contractual termination costs. The remainder of the costs will be non-cash, relating primarily to the accelerated depreciation of facilities. The Company expects the actions under the 2025 Restructuring Program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027. The 2025 Restructuring Program is part of the Company’s multiyear optimization initiative anticipated to achieve $3.0 billion in annual cost savings by the end of 2027, which will be fully reinvested into strategic growth areas of the business.
In January 2024, the Company approved a restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 50% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company anticipates the actions under the 2024 Restructuring Program will result in cumulative annual net cost savings of approximately $750 million by the end of 2031.
Restructuring costs of $184 million and $47 million for the third quarter of 2026 and 2025, respectively, and $530 million and $676 million in the first nine months of 2026 and 2025, respectively, primarily include separation and other costs
- 41 -
associated with these restructuring activities. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Other expenses in Restructuring costs include facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement, and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of $581 million and $390 million in the third quarter of 2026 and 2025, respectively, and $1.4 billion and $1.3 billion in the first nine months of 2026 and 2025, respectively, related to restructuring program activities. See Note 4 to the condensed consolidated financial statements for additional details.
Other (Income) Expense, Net
Other (income) expense, net, was $27 million of expense in the third quarter of 2026 compared with $238 million of income in the third quarter of 2025. Other (income) expense, net, was $262 million of expense in the first nine months of 2026 compared with $281 million of income in the first nine months of 2025. The unfavorable period-over-period changes were primarily due to higher net interest expense, partially offset by higher net income from investments in equity securities.
For details on the components of Other (income) expense, net see Note 11 to the condensed consolidated financial statements.
| Segment Profits | |||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| ($ in millions) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Pharmaceutical segment profits | $ | 13,112 | $ | 12,687 | $ | 36,262 | 34,660 | ||||||||||||||||
| Animal Health segment profits | 541 | 511 | 1,900 | 1,737 | |||||||||||||||||||
| Non-segment activity | (8,094) | (6,453) | (36,820) | (18,750) | |||||||||||||||||||
| Income Before Taxes | $ | 5,559 | $ | 6,745 | $ | 1,342 | $ | 17,647 |
Pharmaceutical segment profits consist of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits consist of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D expenses incurred by MRL, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-related costs, including the amortization of intangible assets and the recognition of fair value step-up of inventories, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Non-segment activity” in the above table. Also included in “Non-segment activity” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements.
Taxes on Income
The effective income tax rate of 8.9% for the third quarter of 2026 reflects the favorable impacts of certain discrete items, as well as jurisdictional mix of income and expense. The income tax provision of $1.9 billion for the first nine months of 2026 on pretax income of $1.3 billion, resulted in an effective income tax rate of 138.2%. The effective income tax rate for the first nine months of 2026 reflects a 126.6 percentage point combined unfavorable impact of the charges for the acquisitions of Cidara and Terns, which had no tax benefits, partially offset by the favorable impacts of certain discrete items, as well as jurisdictional mix of income and expense.
The effective income tax rates of 14.2% and 13.3% for the third quarter and first nine months of 2025, respectively, reflect the favorable impacts of jurisdictional mix of income and expense, as well as certain discrete items.
The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017. In April 2025, Merck received Notices of Proposed Adjustment (NOPAs) that would increase the amount of the one-time transition tax on certain undistributed earnings of foreign subsidiaries by approximately $1.3 billion. In addition, the NOPAs included penalties of approximately $260 million. These amounts are exclusive of any interest that may be due. The Company disagrees with the proposed adjustments and is vigorously contesting the NOPAs through available administrative proceedings. However, it remains uncertain whether a resolution can be reached during this phase of the audit, and judicial proceedings may be necessary. If the Company is ultimately unsuccessful in resolving or defending its position, the impact could be material to its financial statements. The statute of limitations for assessments with respect to the 2019 and 2020 federal tax return years expired in June 2024 and
- 42 -
October 2024, respectively. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress.
Non-GAAP Income and Non-GAAP EPS
Non-GAAP income and non-GAAP earnings per share (EPS) are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance.
Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP).
A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| ($ in millions except per share amounts) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Income before taxes as reported under GAAP | $ | 5,559 | $ | 6,745 | $ | 1,342 | $ | 17,647 | |||||||||||||||
| Increase (decrease) for excluded items: | |||||||||||||||||||||||
| Acquisition- and divestiture-related costs | 1,167 | 659 | 3,303 | 1,900 | |||||||||||||||||||
| Restructuring costs | 581 | 390 | 1,381 | 1,274 | |||||||||||||||||||
| Income from investments in equity securities, net | (393) | (344) | (764) | (512) | |||||||||||||||||||
| Non-GAAP income before taxes | 6,914 | 7,450 | 5,262 | 20,309 | |||||||||||||||||||
| Income tax provision as reported under GAAP | 492 | 958 | 1,855 | 2,346 | |||||||||||||||||||
| Estimated tax benefit on excluded items (1) | 261 | 128 | 737 | 468 | |||||||||||||||||||
| Tax (expense) benefit resulting primarily from audit reserve adjustments | — | (86) | — | 60 | |||||||||||||||||||
| Non-GAAP income tax provision | 753 | 1,000 | 2,592 | 2,874 | |||||||||||||||||||
| Non-GAAP net income | 6,161 | 6,450 | 2,670 | 17,435 | |||||||||||||||||||
| Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP | 2 | 2 | (3) | 10 | |||||||||||||||||||
| Non-GAAP net income attributable to Merck & Co., Inc. | $ | 6,159 | $ | 6,448 | $ | 2,673 | $ | 17,425 | |||||||||||||||
| EPS assuming dilution as reported under GAAP (2)(3) | $ | 2.04 | $ | 2.32 | $ | (0.21) | $ | 6.08 | |||||||||||||||
| EPS difference | 0.45 | 0.26 | 1.29 | 0.85 | |||||||||||||||||||
| Non-GAAP EPS assuming dilution (2) | $ | 2.49 | $ | 2.58 | $ | 1.08 | $ | 6.93 |
(1) The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
(2) GAAP and non-GAAP EPS were negatively affected in the third quarter and first nine months of 2026 by charges of $0.12 per share and $6.05 per share, respectively, for license agreements and transactions accounted for as asset acquisitions. See “Business Development Transactions” above for additional information. GAAP and non-GAAP EPS were negatively affected in the third quarter and first nine months of 2025 by charges of $0.10 per share and $0.16 per share, respectively, for certain upfront and pre-approval milestone payments related to license agreements.
(3) The Company recorded a net loss on a GAAP basis for the first nine months of 2026; therefore, no potential dilutive common shares were used in the computation of loss per common share assuming dilution because the effect would have been antidilutive.
Acquisition- and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and the recognition of fair value step-up of inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations, asset acquisitions, and license agreements, as well as the recognition of fair value step-up of inventories related to asset acquisitions.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 4 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be fully or partially closed or divested. Accelerated depreciation costs represent the difference between the
- 43 -
depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset impairment, facility shut-down, contractual termination, and other related costs, as well as employee-related costs such as curtailment, settlement, and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these items are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2025 is tax (expense) benefit resulting primarily from audit reserve adjustments.
Research and Development Update
The Company currently has several candidates under regulatory review in the U.S. and internationally.
MK-0616, Lipfendra, a once-daily oral PCSK9 inhibitor, is under review in the EU for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia. The application is based on the Phase 3 CORALreef Lipids, CORALreef HeFH, and CORALreef AddOn studies. Lipfendra also is under review in Japan for the treatment of hypercholesterolemia and familial hypercholesterolemia, as well as in China.
MK-2870, sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed ADC, is under priority review by the FDA for the treatment of adult patients with endometrial cancer who have previously received platinum containing chemotherapy and a PD-1 or PD-L1 inhibitor, separately or in combination, The application is based on data from the Phase 3 TroFuse-005 trial. The FDA set a Prescription Drug User Fee Act (PDUFA) date of June 15, 2027. In December 2025, the FDA selected sac-TMT to receive a Commissioner’s National Priority Voucher under a pilot program offering the ability to seek expedited approval based on alignment with one or more critical national health priorities. The Company is in discussions with the FDA and is hopeful for an approval before the PDUFA date.
MK-8591A, Idvynso, a once-daily, oral two-drug regimen of doravirine, a non-nucleoside reverse transcriptase inhibitor, and islatravir, a next-generation nucleoside analog reverse transcriptase inhibitor, for the treatment of certain adults with HIV-1 infection is under review in the EU. The application is based on findings from the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials in adults whose HIV-1 infection is virologically suppressed on antiretroviral therapy, as well as on the MK-8591A-053 clinical trial in previously untreated adults. Idvynso is also under review in the U.S. to expand the approved indication in certain virologically suppressed adults with HIV-1 infection to include certain adults who have not previously received antiretroviral treatment; the FDA set a PDUFA date of April 22, 2027.
MK-1654, Enflonsia, is an extended half-life monoclonal antibody indicated for passive immunization for the prevention of RSV LRTD in newborns and infants who are born during or entering their first RSV season. Enflonsia is under review in the U.S., the EU and Japan to expand the approved indication to include prevention of RSV LRTD in children under two years of age at increased risk for severe RSV disease through their second RSV season. In the U.S., the FDA set a PDUFA date of March 22, 2027.
MK-3475, Keytruda, is an anti-PD-1 therapy available for intravenous administration. MK-3475A, Keytruda Qlex, combines pembrolizumab with berahyaluronidase alfa to enhance dispersion and permeability to enable subcutaneous administration. Keytruda and Keytruda Qlex each are approved for the treatment of many cancers and continue to be studied in additional Phase 3 trials. In the EU and certain other international markets, Keytruda Qlex is approved as a subcutaneous route of administration and pharmaceutical form of Keytruda (marketed as Keytruda SC). Keytruda is under review:
*•*In Japan, in combination with Padcev as neoadjuvant treatment, then continued after radical cystectomy as adjuvant treatment, for patients with MIBC who are ineligible for cisplatin-based chemotherapy. The application is based on data from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer Inc. (Pfizer) and Astellas.
-
In Japan, in combination with Padcev as neoadjuvant treatment, then continued after radical cystectomy as adjuvant treatment, for patients with MIBC who are eligible for cisplatin-based chemotherapy. The application is based on data from the Phase 3 KEYNOTE-B15 trial conducted in collaboration with Pfizer and Astellas.
-
In the EU, in combination with chemotherapy with or without radiation, for the adjuvant treatment of newly diagnosed, mismatch repair deficient endometrial cancer in adults who are at high risk of recurrence. The application is based on data from the Phase 3 KEYNOTE-B21 trial.
MK-6482, Welireg, Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, is under review:
- In the EU and Japan, in combination with Keytruda for the adjuvant treatment of certain patients with clear cell RCC following nephrectomy. The application is based on data from the Phase 3 LITESPARK-022 trial.
- 44 -
- In the EU, in combination with MK-7902, Lenvima, an orally available multiple receptor TKI, for the treatment of certain previously treated patients with advanced RCC. The supplemental application for Welireg is based on data from the Phase 3 LITESPARK-011 trial. In Japan, the combination is under review for Lenvima. Lenvima is being developed as part of a collaboration with Eisai Co., Ltd.
The Biologics License Application (BLA) seeking accelerated approval in the U.S. for MK-2400, ifinatamab deruxtecan (I-DXd), for the treatment of adult patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) who experienced disease progression on or after platinum-based chemotherapy, has been voluntarily withdrawn. I-DXd is an investigational, potential first-in-class B7-H3 directed DXd ADC being developed as part of a collaboration with Daiichi Sankyo. The decision to withdraw the BLA was based on discussions with the FDA that data supporting the application, including from the IDeate-Lung01 Phase 2 trial, do not satisfy requirements needed to support an accelerated approval for the proposed indication. Patient enrollment continues in the IDeate-Lung02 Phase 3 trial evaluating the efficacy and safety of I-DXd versus treatment of physician’s choice of chemotherapy (amrubicin, lurbinectedin or topotecan) in patients with relapsed ES-SCLC following disease progression with only one prior line of platinum-based chemotherapy.
The chart below reflects the Company’s research pipeline as of November 2, 2026. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics generally are given MK-number designations and vaccine candidates generally are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer, immunology and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.
| Phase 2 | ||||||||
| Alzheimer’s Disease MK-2214 Atherosclerosis MK-7262 Cancer MK-1022 (patritumab deruxtecan)(1) Bladder Cervical Esophageal Gastric Melanoma Non-Small Cell Lung MK-1045 Hematological Malignancies MK-1084 (calderasib) Solid Tumors MK-2010 Solid Tumors MK-2400 (ifinatamab deruxtecan)(1) Bladder Endometrial Head and Neck Hepatocellular Melanoma Non-Small Cell Lung Ovarian Solid Tumors | Cancer MK-2870 (sacituzumab tirumotecan) Biliary Esophageal Neoplasm Malignant MK-3475 Keytruda Prostate MK-3475A Keytruda Qlex Hematological Malignancies (U.S.) MK-5684 (opevesostat) Breast Endometrial Ovarian MK-5909 (raludotatug deruxtecan)(1) Cervical Endometrial Gastric Non-Small Cell Lung Small Cell Lung MK-6070 (gocatamig)(1) Small Cell Lung MK-6482 Welireg Breast V940 (intismeran autogene)(1) Bladder Renal Cell | Chronic Obstructive Pulmonary Diseases MK-5884A (ensifentrine+glycopyrrolate) HIV-1 Infection MK-8591B (islatravir+ulonivirine) Immunology MK-7240 (tulisokibart) Axial Spondyloarthritis Hidradenitis Suppurativa Psoriatic Arthritis Rheumatoid Arthritis MK-8690 Ulcerative Colitis Metabolic Dysfunction-Associated Steatohepatitis (MASH) MK-6024 (efinopegdutide) Pulmonary Hypertension Due To Left Heart Disease MK-7962 Winrevair |
- 45 -
| Phase 3 (Phase 3 entry date) | Under Review | |||||||
| Cancer MK-1022 (patritumab deruxtecan)(1) Breast (July 2025) MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1084 (calderasib) Colorectal (July 2025) Non-Small Cell Lung (May 2024) MK-2140 (zilovertamab vedotin) Hematological Malignancies (September 2024) MK-2400 (ifinatamab deruxtecan)(1) Esophageal (March 2025) Prostate (May 2025) Small Cell Lung (July 2024) MK-2870 (sacituzumab tirumotecan) Bladder (April 2026) Breast (April 2024) Cervical (July 2024) Endometrial (EU) (December 2023) Gastric (May 2024) Non-Small Cell Lung (November 2023) Ovarian (April 2025) MK-3475 Keytruda Small-Cell Lung (May 2017) MK-3543 (bomedemstat) Myeloproliferative Disorders (December 2023) MK-5684 (opevesostat) Prostate (December 2023) MK-5909 (raludotatug deruxtecan)(1) Ovarian (December 2025) MK-7339 Lynparza*(1)* Non-Small Cell Lung (June 2019) Small Cell Lung (December 2020) V940 (intismeran autogene)(1) Melanoma (July 2023) Non-Small Cell Lung (December 2023) Chronic Obstructive Pulmonary Diseases MK-5884 Ohtuvayre (EU) (September 2020) COVID-19 MK-4482 Lagevrio (U.S.) (May 2021)(2) Dengue Fever Virus Vaccine V181 (June 2025) Diabetic Macular Edema MK-3000 (remigromig)(3) HIV-1 Infection MK-8591D (islatravir+lenacapavir) (October 2024)(1)(4) HIV-1 Pre-Exposure Prophylaxis MK-8527 (alimatravir) (July 2025) Immunology MK-7240 (tulisokibart) Crohn’s Disease (June 2024) Ulcerative Colitis (October 2023) Influenza MK-1406 (efitazanamivir alfa) (September 2025) Neovascular Age-Related Macular Degeneration MK-8748*(5)* | New Molecular Entities Hypercholesterolemia MK-0616 Lipfendra (EU) (JPN) Previously Treated Endometrial Cancer MK-2870 (sacituzumab tirumotecan) (U.S.) HIV-1 Infection MK-8591A Idvynso (EU) | Certain Supplemental Filings HIV-1 Infection (Treatment Naive) MK-8591A Idvynso (U.S.) Respiratory Syncytial Virus (Second Season) MK-1654 Enflonsia (U.S.) (EU) (JPN) Cancer MK-3475 Keytruda • Cisplatin-Ineligible Muscle Invasive Bladder Cancer (KEYNOTE-905) (JPN) • Cisplatin-Eligible Muscle Invasive Bladder Cancer (KEYNOTE-B15) (JPN) • Newly Diagnosed High-Risk Endometrial Cancer (KEYNOTE-B21) (EU) MK-6482 Welireg • Clear Cell Renal Cell Carcinoma Following Nephrectomy (LITESPARK-022) (EU) (JPN)(6) • Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-011) (EU) (JPN)(1)(7) | ||||||
| Footnotes: (1) Being developed in a collaboration. (2) Available in the U.S. under Emergency Use Authorization, which will terminate effective June 29, 2027. (3) Program is in Phase 2/3 studies, the first of which commenced in August 2024. (4) On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials. (5) Program is in Phase 2/3 studies, the first of which commenced in March 2026. (6) Under review for combination use with Keytruda. (7) Under review in Japan for Lenvima, used in combination with Welireg. |
Analysis of Liquidity and Capital Resources
| ($ in millions) | September 30, 2026 | December 31, 2025 | |||||||||
| Cash and investments | $ | 11,253 | $ | 15,521 | |||||||
| Working capital | 10,140 | 15,189 | |||||||||
| Total debt to total liabilities and equity | 40.5 | % | 36.0 | % |
Cash provided by operating activities was $15.8 billion in the first nine months of 2026 compared with $13.6 billion in the first nine months of 2025. Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases. Larger business development transactions may be funded with a combination of cash from operating activities and debt.
Cash used in investing activities was $17.1 billion in the first nine months of 2026 compared with $2.5 billion in the first nine months of 2025. The higher use of cash in investing activities was primarily due to the acquisitions of Cidara, Terns and TARGAN, partially offset by lower purchases of securities and other investments, lower capital expenditures (driven in part by the acquisition of a facility from WuXi Vaccines in 2025), and higher proceeds from sales of securities and other investments.
Cash used in financing activities was $3.7 billion in the first nine months of 2026 compared with $6.7 billion in the first nine months of 2025. The lower use of cash in financing activities was primarily due to proceeds from a term loan, lower purchases of treasury stock, lower payments on long-term debt, and higher proceeds from the exercise of stock options, partially offset by the repayment of the term loan and higher dividends paid to shareholders.
In April 2026, Merck entered into a delayed draw term loan credit agreement (Credit Agreement) pursuant to which the lenders committed (subject to satisfaction of certain conditions set forth in the Credit Agreement) to provide Merck with financing under a 364-day term loan facility in an aggregate amount not to exceed $6.0 billion. The Company drew down the full
- 46 -
$6.0 billion of funds under the facility to fund a portion of the approximately $6.8 billion cash consideration for the acquisition of Terns. The Company has since repaid borrowings under the Credit Agreement.
In May 2026, the Company issued $6.0 billion aggregate principal amount of senior unsecured notes consisting of $500 million of floating rate notes due 2028, $1.0 billion of 4.30% notes due 2028, $500 million of 4.65% notes due 2031, $1.0 billion of 4.95% notes due 2033, $1.5 billion of 5.20% notes due 2036, $500 million of 5.75% notes due 2046, and $1.0 billion of 5.85% notes due 2056. The Company used the net proceeds from the offering to repay borrowings under the Credit Agreement as noted above.
In January 2026, February 2026, and October 2026, the Company’s $135 million, 6.30% debentures, its $1.0 billion, 0.75% notes, and its 1.0 billion, euro-denominated notes, respectively, matured in accordance with their terms and were repaid. In February 2025, the Company’s $2.5 billion, 2.75% notes matured in accordance with their terms and were repaid.
Dividends paid to stockholders were $6.3 billion and $6.2 billion in the first nine months of 2026 and 2025, respectively. In May 2026, Merck’s Board of Directors declared a quarterly dividend of $0.85 per share on the Company’s outstanding common stock for the third quarter of 2026 that was paid in July 2026. In July 2026, Merck’s Board of Directors declared a quarterly dividend of $0.85 per share on the Company’s outstanding common stock for the fourth quarter of 2026 that was paid in October 2026.
In January 2025, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. During the first nine months of 2026, the Company purchased $2.3 billion (19 million shares) of its common stock for its treasury under this program. The Company expects to repurchase approximately $3.0 billion of treasury shares under this program during 2026. As of September 30, 2026, the Company’s remaining share repurchase authorization was $5.1 billion.
The Company has a $6.0 billion credit facility that matures in May 2031. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Estimates
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2025 included in Merck’s Form 10‑K filed on February 24, 2026. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates is included in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K. There have been no significant changes in the Company’s critical accounting estimates since December 31, 2025.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Previous: Item 1. Financial Statements · Next: Item 3. Quantitative and Qualitative Disclosures about Market Risk